(Q53080275)

11 May 2018

meta-analysis

0 references

title

Factors modifying drug and placebo responses in randomized trials for bipolar mania. (English)

1 reference

11 May 2018

1 reference

2

1 reference

11 May 2018

author name string

Ayşegül Yildiz

series ordinal

1

1 reference

11 May 2018

Mauricio Tohen

series ordinal

3

1 reference

11 May 2018

Ross J Baldessarini

series ordinal

4

1 reference

11 May 2018

publication date

7 February 2011

1 reference

11 May 2018

The International Journal of Neuropsychopharmacology

published in

1 reference

11 May 2018

volume

14

1 reference

11 May 2018

issue

7

1 reference

11 May 2018

page(s)

863-875

1 reference

11 May 2018

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Research diagnostic criteria: rationale and reliability

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebo-controlled replication trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Introduction to Meta-Analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Valproate in the treatment of acute mania. A placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A random-effects regression model for meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

STATISTICAL TREATMENT OF THE LAW OF INITIAL VALUES (LIV) IN AUTONOMIC RESEARCH: A REVIEW AND RECOMMENDATION.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Asenapine versus olanzapine in acute mania: a double-blind extension study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Quetiapine or haloperidol as monotherapy for bipolar mania--a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Ethical questions in human clinical psychopharmacology: should the focus be on placebo administration?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A rating scale for mania: reliability, validity and sensitivity

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Psychobiology of the placebo response

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Risperidone in the treatment of acute mania: double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Limitations of applying summary results of clinical trials to individual patients: the need for risk stratification

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Statistics review 5: Comparison of means

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Placebo effect in randomized, controlled studies of acute bipolar mania and depression

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Increasing rates of placebo response over time in mania studies.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Verapamil for the treatment of acute mania: a double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Lamotrigine: a review of its use in bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A diagnostic interview: the schedule for affective disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007).

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

The use of placebos in randomized clinical trials of mood disorders: well justified, but improvements in design are indicated

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710001641

7 January 2021

10.1017/S1461145710001641

Identifiers

DOI

1 reference

11 May 2018

1 reference

11 May 2018